Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

Yerel katalogda bu makaleye atıf yapan 12 yayın (OpenAlex referans eşleşmesi; tam dünya listesi değildir).

1. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer 2024 Atıf 1.057 · OpenAlex
2. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial 2021 Atıf 660 · OpenAlex
3. Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma 2023 Atıf 505 · OpenAlex
4. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial 2020 Atıf 505 · OpenAlex
5. PILE: a candidate prognostic score in cancer patients treated with immunotherapy 2021 Atıf 28 · OpenAlex
6. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy 2021 Atıf 23 · OpenAlex
7. Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma 2024 Atıf 9 · OpenAlex
8. PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer 2021 Atıf 7 · OpenAlex
9. PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer 2021 Atıf 7 · OpenAlex
10. The Impact of Fibroblast Growth Factor Receptor Alterations in Clinical Outcomes of Patients With Advanced Urothelial Carcinoma: Real-World Data From a Latin American Population 2024 Atıf 2 · OpenAlex